News
The poster highlights the potential for ARV-393 to be combined with various standard of care lymphoma treatments. ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback